<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29348">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724644</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-201</org_study_id>
    <nct_id>NCT02724644</nct_id>
  </id_info>
  <brief_title>EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)</brief_title>
  <official_title>EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, effectiveness, and immunogenicity of EN3835 in the
      treatment of adult women with Edematous Fibrosclerotic Panniculopathy (Commonly known as
      Cellulite).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of composite responders with a 2 level improvement at Day 71</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with an improvement in severity from baseline (Day 1 visit) of at least 2 levels of severity in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) (5-point scale ranging from ) [no cellutlite] to 4 [severe cellulite] and at least 2 levels of severity in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) 5-point scale ranging from 0 [no cellulite] to 4 [severe cellulite]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of composite responders with a 1 level improvement at Day 71</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with an improvement in severity from baseline (Day 1 visit) of at least 1 level of severity in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS): 5-point scale ranging from 0 (no cellulite) to 4 (severe cellulite) and at least 1 level of severity in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS): 5-point scale ranging from 0 (no cellulite) to 4 (severe cellulite).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with 2 levels of improvement in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS)</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders defined as subjects with an improvement in severity from baseline of at least 2 levels of severity in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS): 5-point scale ranging from 0 (no cellulite) to 4 (severe cellulite).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with one level of improvement in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS)</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with an improvement in severity from baseline of at least 1 level of severity in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS): 5-point scale ranging from 0 (no cellulite) to 4 (severe cellulite).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with improvement in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS)</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with an improvement in severity from baseline of at least 2 levels of severity in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS): 5-point scale ranging from 0 (no cellulite) to 4 (severe cellulite).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with one level improvement in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS)</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with an improvement in severity from baseline of at least 1 level of severity in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS): 5-point scale ranging from 0 (no cellulite) to 4 (severe cellulite).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders at each level of the Investigator Global Aesthetic Improvement Scale (I-GAIS)</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with a response of 1 (improved) or better in the Investigator Global Aesthetic Improvement Scale (I-GAIS) assessment: 7-point scale ranging from -3 (very much worse) to 3 (very much improved)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responses at each level of the Subject Global Aesthetic Improvement Scale (S-GAIS)</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders defined as subjects with a response of 1 (improved) or better in the Subject Global Aesthetic Improvement Scale (S-GAIS) assessment: 7-point scale ranging from -3 (very much worse) to 3 (very much improved)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders at each level of the subject satisfaction with cellulite treatment assessment</measure>
    <time_frame>Day 71</time_frame>
    <description>Responders are defined as subjects with a change at each level in satisfaction with Cellulite Treatment Assessment: 5-point scale ranging from -2 (very much dissatisfied) to 2 (very much satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Hexsel CSS total score from day 1 (Baseline) to Day 71</measure>
    <time_frame>Baseline and Day 71</time_frame>
    <description>Investigator rating of cellulite severity using the total score from the Hexsel Cellulite Severity Scale (CSS): scores can range from 0 (no cellulite) to 15 (extremely severe cellulite).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>EN3835 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EN3835 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COLLAGENASE CLOSTRIDIUM HISTOLYTICUM</intervention_name>
    <description>Injectable intervention</description>
    <arm_group_label>EN3835 Active</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <arm_group_label>EN3835 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a female â‰¥18 years of age

          -  At Screening visit, have at least 1 quadrant with:

               -  a score of 3 or 4 (moderate or severe) as reported by the subject (PR- PCSS),
                  and

               -  a score of 3 or 4 (moderate or severe) as reported by the Investigator
                  (CR-PCSS), and

               -  a Hexsel CSS score no greater than 13

          -  At Day 1 visit, have an assigned quadrant with:

               -  a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and

               -  a score of 3 or 4 (moderate or severe) as reported by the Investigator
                  (CR-PCSS), and

               -  a Hexsel CSS score no greater than 13

          -  Be willing to apply sunscreen to the selected treatment quadrant before each exposure
             to the sun while participating in the study (ie, screening through end of study).

          -  Be judged to be in good health, based upon the results of a medical history, physical
             examination, and laboratory profile at screening

          -  Have a negative urine pregnancy test at screening and be using an effective
             contraception method (eg, abstinence, intrauterine device [IUD], hormonal
             [estrogen/progestin] contraceptives, or double barrier method) for at least 1
             menstrual cycle prior to study enrollment and for the duration of the study; or be
             menopausal defined as 12 months of amenorrhea in the absence of other biological or
             physiological causes, as determined by the investigator; or post-menopausal for at
             least 1 year; or be surgically sterile.

          -  Be willing and able to cooperate with the requirements of the study

          -  Voluntarily sign and date an informed consent agreement approved by the Institutional
             Review Board/Independent Ethics Committee/Human Research Ethics Committee
             (IRB/IEC/HREC).

          -  Be able to read, complete and understand the Patient Reported Outcomes rating
             instruments in English

        Exclusion Criteria:

          -  Has any of the following conditions:

               -  Thyroid disease, unless controlled with medication for â‰¥6 months

               -  Uncontrolled diabetes mellitus, as determined by the Investigator

               -  Uncontrolled hypertension, as determined by the Investigator

               -  Vascular disorder (eg, phlebitis or varicose veins) in area to be treated

               -  Cushing's disease and/or use of systemic corticosteroids at a total daily dose
                  greater than 5 mg prednisone (or equivalent)

               -  History of lower extremity thrombosis or post-thrombosis syndrome

               -  Documented autoimmune disorder such as lupus erythematosus, rheumatoid arthritis

               -  Inflammation or active infection in area to be treated

               -  Active cutaneous alteration in area to be treated including rash, eczema,
                  psoriasis or skin cancer

               -  History of keloidal scarring or abnormal wound healing

               -  Coagulation disorder

               -  Taking a medication for chronic anticoagulation (except for â‰¤150 mg aspirin
                  daily)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Testing of Beverly Hills</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists, Inc</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists, Inc</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Cosmetic Laser Medical Associates of LaJolla, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bass Plastic Surgery, PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 16, 2017</lastchanged_date>
  <firstreceived_date>March 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
